Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (10023)	9/29/2015 2:44:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

xncr, <3.5 ttph, <1.5 mgnx, not certain but it may also be around 3.5. And, given timing of the raise, even ex-darling blue is ~ 3.5. Just examples, please give more. Anyone and everyone ass'd with the sector for years? They know what it means when price:book gets this low.... blood-from-stones time is coming. The U.S. pharmaceutical pricing system drives innovation in medicines. Balance is key, and it's a tragedy that aholes want to violate the "ethical" part of ethical pharma.... hard work and solid research first, profits follow.

To: scaram(o)uche who wrote (10023)

9/29/2015 5:07:00 PM

From: The Ox

Read Replies (1) | Respond to of 12215

PTCT has come down to the 3.5 P/B level. They have been on my radar for some time now and starting to appeal to this observer....might be time to nibble on this one.